TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Stand & Move at Work: A Group Randomized Trial
Brief Summary: A trial testing the efficacy of sit-stand workstations on decreasing sitting time and increasing light-intensity physical activity in samples of office worksites.


Options:
A: Body Weight (4 months); Body Weight (7 Months)
B: Mean Change in Light-intensity Physical Activity at Work From Baseline to 12 Months (1 year); Mean Change in Sitting Time at Work From Baseline to 12 Months (1 year)
C: muscle strength (3 months); Aerobic capacity (3 months)
D: EQ-5D (Baseline, change in EQ-5D at 6 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Stand & Move at Work: A Group Randomized Trial
Brief Summary: A trial testing the efficacy of sit-stand workstations on decreasing sitting time and increasing light-intensity physical activity in samples of office worksites.


Options:
A: Incidence of CHD and other lifestyle related diseases after ten years (2012)
B: Change from baseline in physical activity and sedentariness at 12 months (Baseline, 12 months)
C: Mean Change in Light-intensity Physical Activity at Work From Baseline to 12 Months (1 year); Mean Change in Sitting Time at Work From Baseline to 12 Months (1 year)
D: sitting time (one week); self-reported context-specific sitting time (one week); standing time (one week); breaks from sitting (one week)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Multicentre, Randomised, Double-Blind, Placebo Controlled, Crossover Trial On The Efficacy Of A Mixture Of Three Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders
Brief Summary: Abdominal pain (AP)-associated functional gastrointestinal disorders (FGIDs), particularly Irritable Bowel Syndrome (IBS) and Functional Dyspepsia (FD), are common in pediatrics, and no safe and effective treatment is available. Although probiotics have shown promising results in adults, few studies have been published in children. The Bifidobacterium Infantis, Bifidobacterium Breve and Bifidobacterium Longum are the most important beneficial bacteria in children and represent 95% of the total bacterial population in the intestine of breastfed infant.

Objectives: 1) To evaluate the effect of oral administration of a mixture of Bifidobacteria on the improvement of frequency and intensity of AP in children with FD and IBS. 2) To evaluate the effect of oral administration of a mixture of Bifidobacteria on quality of life in children with FD and IBS.


Options:
A: Abdominal Pain Frequency (16 weeks from the enrollment)
B: Frequency and intensity of abdominal pain (Eight weeks)
C: Intensity of abdominal pain (3 months); Severity of chronic constipation (3 months)
D: The primary outcome measure was defined as reduction of pain (both number of episodes and intensity) at the end of the intervention. (12 weeks and 20 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Multicentre, Randomised, Double-Blind, Placebo Controlled, Crossover Trial On The Efficacy Of A Mixture Of Three Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders
Brief Summary: Abdominal pain (AP)-associated functional gastrointestinal disorders (FGIDs), particularly Irritable Bowel Syndrome (IBS) and Functional Dyspepsia (FD), are common in pediatrics, and no safe and effective treatment is available. Although probiotics have shown promising results in adults, few studies have been published in children. The Bifidobacterium Infantis, Bifidobacterium Breve and Bifidobacterium Longum are the most important beneficial bacteria in children and represent 95% of the total bacterial population in the intestine of breastfed infant.

Objectives: 1) To evaluate the effect of oral administration of a mixture of Bifidobacteria on the improvement of frequency and intensity of AP in children with FD and IBS. 2) To evaluate the effect of oral administration of a mixture of Bifidobacteria on quality of life in children with FD and IBS.


Options:
A: The primary outcome measure was defined as reduction of pain (both number of episodes and intensity) at the end of the intervention. (12 weeks and 20 weeks)
B: Abdominal Pain Frequency (16 weeks from the enrollment)
C: Average daily abdominal pain frequency (9 days (2 dietary intervention periods))
D: Improvement in pain and stooling symptoms (The last two weeks of treatment and up to 18 months after treatment)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala
Brief Summary: This project plans to learn more about whether sending text messages to parents on their mobile phones to remind them when their child is due for his or her next vaccination will improve children getting vaccinated on time.


Options:
A: Completion of vaccine primary series (12 months of age)
B: Self-reported completion of a full course of PEP medications and receipt of a final HIV test result from their nPEP provider 12 weeks after the index exposure (12 weeks)
C: Cumulative adverse event (AE) rate (moderate or severe) (≤ Day 14 for each participant with analysis completed in year 1.); Mean number of in-person visits (Before 42 day visit for each participant with analysis completed in year 1.); 2wT costs (The costing data collection will be completed by April 2018 at the completion of all study participant follow-up. Analysis will conclude in year 1); 2WT acceptability (The acceptability activities will be completed by April 2018 at the completion of all study participant follow-up with analysis to commence after that point. Analysis will conclude in year 1.); 2WT feasibility (The feasibility activities be completed by April 2018 at the completion of all study participant follow-up with analysis to commence after that point. Analysis will conclude in year 1.)
D: Change in Exclusive Breastfeeding Rate (2 weeks after birth); Change in Exclusive Breastfeeding Rate (3 months after birth); Change in Exclusive Breastfeeding Rate (6 months after birth)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala
Brief Summary: This project plans to learn more about whether sending text messages to parents on their mobile phones to remind them when their child is due for his or her next vaccination will improve children getting vaccinated on time.


Options:
A: Adherence to cervical cancer screening (step1) (Up to 20 months)
B: Completion of vaccine primary series (12 months of age)
C: Adherence (Change from baseline at 6 months)
D: Mammogram receipt (1 week)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala
Brief Summary: This project plans to learn more about whether sending text messages to parents on their mobile phones to remind them when their child is due for his or her next vaccination will improve children getting vaccinated on time.


Options:
A: Difference in Number and proportion of adults responding to standard appointment versus intense follow up. (2 weeks)
B: Completion of vaccine primary series (12 months of age)
C: Receipt of 2nd Dose of the Influenza Vaccine. (by April 30th after receipt of first dose (up to 8 months))
D: the first aim is to assess our ability to enroll at least 70% (N=90) of eligible parents in a text messaging program (up to 1 year)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala
Brief Summary: This project plans to learn more about whether sending text messages to parents on their mobile phones to remind them when their child is due for his or her next vaccination will improve children getting vaccinated on time.


Options:
A: Vaccines received (Electronic Health Record) (up to a year of follow up)
B: Completion of vaccine primary series (12 months of age)
C: Immunization Rates at 14 weeks (14 Weeks)
D: Proportion of fully immunized children (When the participants reach 2 years of age)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala
Brief Summary: This project plans to learn more about whether sending text messages to parents on their mobile phones to remind them when their child is due for his or her next vaccination will improve children getting vaccinated on time.


Options:
A: Acceptability of at least one method of effective contraception (4 months)
B: The rate of the Exclusive Breastfeeding (from birth of baby to 6 months post birth)
C: Completion of 3 Doses of Pentavalent Vaccine (8 months of age)
D: Completion of vaccine primary series (12 months of age)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: The Effects of Gait Retraining in Runners With Patellofemoral Pain: A Randomized Trial
Brief Summary: The purpose of this study is to determine whether changing foot strike pattern from a rearfoot strike to a forefoot strike reduces chronic running-related knee pain. It is believed that switching foot strike pattern from a rearfoot strike to a forefoot strike pattern will reduce associated running-related patellofemoral knee pain.


Options:
A: Change in Strength (Week 0, Week 8); Change in Running Mechanics (Week 0, Week 8); Change in Postural Control (Week 0, Week 8)
B: Knee Extension Strength (Baseline, 8-weeks, 16-weeks and 24-weeks); Participation Rate (Duration of the 8-week intervention for both study groups (week 1 to 8 for intervention group, week 9 to 16 for control group.)
C: Pain (6 weeks)
D: Running-related injury (First-time) (6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Early Childhood Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy
Brief Summary: This is a prospective interventional study involving young children who will all receive non-invasive, passive assessments of sensory and motor function. In addition a subpopulation of young children with cerebral palsy will participate in a randomized controlled trial of constraint-induced movement therapy, a routinely prescribed therapy used in clinical practice for children with motor difficulties. The study attempts to apply a rigorous scientific approach to study a widely used but poorly studied practice. The design is an RCT with wait-list controls to allow all children to benefit from the therapy, even if they are randomized to the control group. All children, regardless of group allocation will continue with their standard of care occupational and physical therapy throughout the study.


Options:
A: Bruininks-Oseretsky Test of Motor Proficiency (BOTMP) (4 weeks (post-treatment), 12 week, 24 week); Peabody Development Motor Scales, subtest fine motor (PDMS-Ⅱ) (4 weeks (post-treatment), 12 week, 24 week); Kinematic analysis (4 weeks (post-treatment), 12 week, 24 week)
B: Assistive Hand Assessment (after two months of treatment)
C: Change in Score on Assisting Hand Assessment (AHA) (Baseline, 6 months); Change in Score on the Jebsen-Taylor Test of Hand Function (JTTHF) (Baseline, 6 months)
D: Kinematics of reach (Change from Baseline to Post intervention (1 month), and 6 months later); Somatosensory processing measurement by ERP (Change from Baseline to Post intervention (1 month), and 6 months later); Bayley Scales of Infant and Toddler Development (Bayley III) - 3rd Edition (Change from Baseline to Post intervention (1 month), and 6 months later)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Phone-based Intervention Under Nurse Guidance After Stroke
Brief Summary: This research seeks to develop a culturally-acceptable, effective, and sustainable way of utilizing the rapidly growing penetration of mobile phones among people in Sub-Saharan Africa (SSA), to improve the currently poor control of hypertension among patients at high risk for future stroke. It also aims to develop human capital in SSA to conduct locally-relevant, high-quality stroke research in the future. Specifically, this study will preliminarily test a strategy that incorporates mobile phone texting and home blood pressure monitoring directed by trained nurses, to improve patient adherence to proven medical therapies for treating hypertension.


Options:
A: Global measure of lifestyle behavior (Health Promoting Lifestyle Profile II) (End of program (6 months))
B: Major vascular event consisting of nonfatal stroke, nonfatal major coronary event and vascular death (Up to 6 years from inclusion)
C: Recruitment rates (9 months); Patient Satisfaction Scales (9 months); Clinic based Blood Pressure (9 months); Retention rates (9 months)
D: Blood Pressure (12 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Evaluation of Low-Level Laser Therapy (LLLT) Effectiveness in Accelerating Orthodontic Tooth Movement For Dental Crowding Cases: A Randomized Controlled Clinial Trial
Brief Summary: 26 participants from the Orthodontic Department at University of Damascus Dental School will be randomly assigned into two groups. In the experimental group, a low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. Laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 j per each tooth. Control group will undergo typical orthodontic treatment with the laser device applied the same manner but without being turned on (to get the placebo effect for pain reduction effect). This procedure will be repeated after 3, 7, 14 days and each 15 days from the beginning of the second month till the end of the leveling and alignment stage.


Options:
A: Changes in the Expression of Salivary Biomarkers of Bone Remodeling (Up to Week 17 of alignment (From T0 to T3)); Alignment of Mandibular Anterior Teeth (Up to Week 17)
B: Duration of fixed appliance orthodontic treatment (Completion of orthodontic treatment, an expected average of 24 months.)
C: Overall Leveling and Alignment Time (OLAT) (This will be measured once the leveling and alignment stage of the orthodontic treatment is finished. This will be measured in days from the commencement of treatment till the final day of leveling and alignment.); Change in Leveling and Alignment Improvement Percentage (LAIP) (this outcome will be measured after one month (T1) and two months (T2) of treatment commencement (T0), and at the end of leveling and alignment stage (T3) using Little irregularity index (LII))
D: The Rate of Orthodontic Movement of a Maxillary Canine Tooth Being Distalized to Close an Extraction Space. (Time to Space Closure, an average of 22 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease
Brief Summary: Non-alcoholic fatty liver disease (NAFLD) is a condition where accumulation of fat in the liver leads to metabolic dysfunction. Currently there are no approved treatments for NAFLD. Part of the metabolic dysfunction may arise through changes in the gut microbiota. Prebiotic fibres have beneficial effects on glucose tolerance, body weight, and gut microbiota; therefore they may have potential as part of a dietary strategy for NAFLD treatment.


Options:
A: The Primary endpoint will be improvement in a composite score of histological injury as measured by the NASH Activity Score (NAS). (approximately 12 months from enrollment)
B: Serum alanine transaminase level decrease min. 0.3 upper limit of normal (6 months)
C: Change in Liver Fat (24 weeks); Change in Liver Fibrosis (24 weeks); Change in Liver Injury (24 weeks)
D: Histological Response Defined by Change From Baseline in Standardized Scoring of Liver Biopsies (12 months); Alanine Transaminase (ALT) Levels (3 month endpoint); Alanine Transaminase (ALT) Levels (6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Comparison Between Celox Versus Bakri Balloon for Treatment of Primary Atonic Postpartum Hemorrhage
Brief Summary: Postpartum hemorrhage (PPH) is responsible for around 25% of maternal mortality worldwide reaching as high as 60% in some countries.

Postpartum hemorrhage is defined as loss of 500 mL or more in a vaginal delivery and 1 Litre or more in a cesarean delivery.Also any blood loss that cause hemodynamic instability should be considered a PPH.

In 2012, WHO updated the guidelines for the management of PPH and retained placenta to include: "The use of intrauterine balloon tamponade is recommended for the treatment of PPH due to uterine atony. This recommendation is now stronger than the previous guidelines. It can be used for women who do not respond to uterotonics or if uterotonics are not available. This procedure potentially can avoid surgery and is appropriate while awaiting transfer to a higher-level facility".Furthermore, FIGO included Uterine balloon tamponade as a recommended second-line intervention for the treatment of PPH in their updated guidelines issued in 2012.

In 2006, the ACOG Practice Bulletin, published by the American College of Obstetricians and Gynecologists, made mention of the Bakri postpartum balloon for its specifically tailored design that enables conservative management of uterine bleeding in cases of uterine atony and other causes of PPH.

The reports demonstrated that balloon tamponade is helpful in managing PPH secondary to a wide variety of causes in resource-poor settings.

One of the new methods that could be used to control PPH is Uterine packing with chitosan-covered gauze or Celox.

Celox Haemostats are dressings with natural material called chitosan to control major haemorrhage including life-threatening bleeding . They are simple and effective, stopping major bleeding.It was first used by military forces to stop sever bleeding in the scene with no other options to stop bleeding. Celox™ granules are actually very high surface area flakes. When they come in contact with blood, Celox™ swells, gels, and sticks together to make a gel like clot, without generating any heat. Celox™ does not set off the normal clotting cascade, it only clots the blood it comes directly into contact with. Celox works on casualties using anticoagulants and anti-platelet therapy such as aspirin .


Options:
A: Frequency of mortalities and frequency of severe morbidities combined as extreme adverse outcomes (during hospital stay)
B: Estimation of blood loss: (during the operation)
C: intraoperative blood loss (during the operation)
D: Amount of blood loss (mL) (8 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: STandard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial (Principal Trial)
Brief Summary: The objectives of this trial are to determine whether, in critically ill patients with severe acute kidney injury (AKI), randomization to accelerated initiation of renal replacement therapy (RRT), compared to standard initiation, leads to:

1. Improved survival (primary outcome); and
2. Recovery of kidney function (principal secondary outcome), defined as independence from RRT at 90 days


Options:
A: Overall survival (60 days)
B: All-cause Mortality. (90 days following study randomization.)
C: Death (90 days)
D: overall mortality (90 days)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: ART and Hall Technique for the Management of Occlusal-proximal Caries in Primary Molars: A Randomized Clinical Trial
Brief Summary: The aim of this, two-arm, parallel group, patient-randomised controlled, superiority trial is to evaluate the survival rate of approximal Atraumatic Restorative Treatment (ART) restorations compared to the Hall Technique (HT) placed in a school setting. The investigators will recruit 120 schoolchildren (5-10 years) with at least one occlusal-proximal carious lesion in primary molar. They will be randomized and treated following best-practice protocols to either receive an ART restoration using the high-viscosity glass ionomer cement (EQUIA Forte, capsules, GC Corp.) or a preformed metal crown placed using the HT (3M ESPE) cemented with glass ionomer luting cement (Fuji I Capsules, GC Corp.). Baseline measures and outcome data (at reviews over a three year period) will be assessed through participant report, clinical examination and parent report/ questionnaires.


Options:
A: Pair-wise radiographic lesion progression (1, 2, and 3 years)
B: Primary outcome is whether the treatment can be made with a maintained sensible pulp and without root infection following a 1-year control. (1year control data for all treatments primo 2008)
C: The restoration survival (changes from baseline up to 36 months) (The treatments will be evaluated after 1 week up to 36 months)
D: Caries Activity and Progression Assessment Using LASER Fluorescence Readings by Diagnodent® Device. (6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
Brief Summary: This is a randomized double-blind placebo controlled trial which aims to evaluate the efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS. Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to Treatment as Usual in an operationalized ARMS population in Pakistan:


Options:
A: time to clinical relapse (52 weeks)
B: Transition to psychotic disorder (12 Months)
C: Number of Participants With Invasive Cancer of Any Type (5 years); Number of Participants With a Major Cardiovascular Event (5 years)
D: cardiovascular deaths and hospitalization for cardiovascular causes (5 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
Brief Summary: This is a randomized double-blind placebo controlled trial which aims to evaluate the efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS. Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to Treatment as Usual in an operationalized ARMS population in Pakistan:


Options:
A: cardiovascular deaths and hospitalization for cardiovascular causes (5 years)
B: Transition to psychotic disorder (12 Months)
C: Change in Liver Fat (baseline and 12 months); Change in Enhanced Liver Fibrosis Score (ELF) (baseline and 12 months); Change in NAFLD Fibrosis Score (baseline and 12 months); Change in Bifidobacterium Spp. (baseline and 12 months)
D: time to clinical relapse (52 weeks)

Answer: B